Sage Therapeutics Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Sage Therapeutics, Inc. |
| Form Type | 10-Q |
| Filed Date | Apr 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, collaboration, equity-compensation
TL;DR
Sage Therapeutics filed its Q1 2025 10-Q, showing financial updates and details on its Biogen deal.
AI Summary
Sage Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates, including information related to its Biogen Collaboration Agreement and various stock-based compensation plans like RSUs and employee stock options. The company's financial position is further detailed through accounts such as Additional Paid-In Capital and Retained Earnings.
Why It Matters
This filing provides investors with a crucial update on Sage Therapeutics' financial health and ongoing business activities, including key collaborations and equity structures.
Risk Assessment
Risk Level: medium — The company operates in the highly regulated and competitive pharmaceutical industry, facing inherent risks related to drug development, clinical trials, and market approval.
Key Numbers
- N/A — Revenue (Specific revenue figures are not detailed in the provided header information.)
- N/A — Net Income (Specific net income figures are not detailed in the provided header information.)
- N/A — Cash Flow (Specific cash flow figures are not detailed in the provided header information.)
Key Players & Entities
- Sage Therapeutics, Inc. (company) — Filer of the 10-Q
- Biogen (company) — Partner in a collaboration agreement
- 20250331 (date) — End of the reporting period
- 20250429 (date) — Filing date
FAQ
What is the current status of the Biogen Collaboration Agreement?
The filing references the Biogen Collaboration Agreement with dates ranging from 2020-01-01 to 2024-12-31, and specifically mentions License and Milestone Revenue related to it for January 2024.
What types of equity compensation are detailed in the filing?
The filing mentions Restricted Stock Units (RSUs), Employee Stock Options, and the Two Thousand Fourteen Employee Stock Purchase Plan.
When was the Sales Agreement entered into?
A Sales Agreement is referenced with the date 2024-09-16.
What is the company's fiscal year end?
Sage Therapeutics, Inc.'s fiscal year ends on December 31st.
What is the company's primary SIC code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on April 29, 2025 regarding Sage Therapeutics, Inc..